TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sleep Disordered Breathing in Gulf War Illness and the Effect of Nasal CPAP Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First Gulf War veterans with and without the syndrome~* Males~* Between 32 and 52 years of age~* No history of current alcoholism nor opiate use~* No history of current active depression nor post-traumatic stress disorder (PTSD)~Exclusion Criteria:~* Females~* History of active alcoholism or opiate drug use~* History of active depression and PTSD

- Gender: MALE
- Minimum Age: 32 Years
- Maximum Age: 52 Years
- Healthy Volunteers: f

Study Arms:
- Therapeutic nasal CPAP (Type: ACTIVE_COMPARATOR): Comparing change of veterans reported outcomes before and after 3 weeks treatment of therapeutic nasal CPAP with the change on sham nasal CPAP.
- Sham nasal CPAP (Type: SHAM_COMPARATOR): Comparing change of symptoms and veterans reported outcomes before and after treatment of 3 weeks on sham nasal CPAP with the change on therapeutic nasal CPAP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bi-PAP vs Sham Bi-PAP on Pulmonary Function in Morbidly Obese Patients After Bariatric Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients have been Morbidly Obese (BMI\> 40kg/m2) for at least 10 years~* All patients had unsuccessfully tried to lose weight by other non-invasive means.~* All patients enrolled were continuous positive airway pressure (CPAP) and Bi-PAP naïve and had no knowledge about the Bi-PAP apparatus prior to enrollment~* All patients underwent OBS (gastroplasty by Mason or gastric bypass) by the same operating team~* All patients were treated with the same standard anesthetic protocol~Exclusion Criteria:~* Cardiovascular and pulmonary disease not related to obesity status~* Chronic renal disease~* Patients who were initially enrolled but did not use the allocated device (Bi-PAP or Sham Bi-PAP) for at least 12 h daily were also excluded at a later point.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sham Bi-PAP (Type: SHAM_COMPARATOR): Sham Bi-PAP was applied through nasal mask for 3 days postoperatively. Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of Bi-PAP. With this modality, also used on previous studies, the applied pressure by sham Bi-PAP was constant and equal to 2 centimeter of water (cm H2O).
- Bi-PAP (Type: ACTIVE_COMPARATOR): Bi-PAP through nasal mask, at individualized IPAP/EPAP pressures, was applied for 3 days postoperatively. IPAP and EPAP in the Bi-PAP system were individualized for each patient in accordance with accepted values of SpO2, PaCO2, and patient synchronization and tolerability with the device.Individualized setting of pressures in patient group was applied gradually starting with 12/4 cm H2O (IPAP/EPAP) and up to 18/10 (IPAP/EPAP) with consecutive increases of 2 cm H2O.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HL-085 in NRAS-mutated Advanced Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 Years or older (male or female).~* Patients have histologically or cytologically confirmed Unresectable stage III or IV melanoma;~* Able to provide the genetic test report with documented NRAS mutation at baseline.~* At least one target lesion as per RECIST v1.1 criteria.~* Previous chemotherapy, immunotherapy, or radiotherapy must have been completed at least 4 weeks prior to study drug administration, and all related toxic reactions (with the exception of alopecia) must have been resolved (to Grade ≤1 or baseline) prior to study drug administration.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.~* Life expectancy \> 3 months.~* No major surgery (excluding baseline tumor biopsy) or major trauma occurred at least 14 days prior to study drug administration.~Exclusion Criteria:~* Patients with active central nervous system (CNS) lesions (i.e., radiological evidence of instability, symptomatic lesions) should be excluded. Note: Patients receiving stereotactic brain radiotherapy or surgery who have shown no brain disease progression over a period of 3 months or longer are eligible for inclusion.~* Patients had received any other study treatment within the past 4 weeks prior to study drug administration.~* Inability to swallow the capsule, refractory nausea and vomiting, malabsorption, extracorporeal biliary shunt, or any small intestinal resection that would preclude adequate absorption of the study drug.~* ECG QTcB ≥ 480 msec (adjusted by Bazetts formula) during screening, or a history of congenital long QT syndrome.~* Bleeding symptoms of Grade 3 as defined by the National Cancer Institute General Terminology Standard for Adverse Events (NCI CTCAE V5.0) within the past 4 weeks prior to study initiation.~* One of the following situations occurs within the past 6 months prior to administration of study drug: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass grafting, symptomatic congestive heart failure, serious arrhythmia, uncontrolled hypertension, cerebrovascular accident, or transient ischemic attack, or symptomatic pulmonary embolism.~* Current use of other anti-cancer drugs (hormone therapy was acceptable).~* Uncontrolled concomitant diseases or infectious diseases.~* Patients have retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED) or other retinal diseases previously or currently.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HL-085 (Type: EXPERIMENTAL): 12 mg BID HL-085

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 18 years and \< 65 years who present with an acute episode of TTP~* Evidence of microangiopathic haemolytic anaemia~* Thrombocytopenia with a normal clotting screen~* Raised Lactate Dehydrogenase (one and a half time above upper normal)~* Patients without neurological dysfunction able to give informed consent~* Patients of reproductive age (must avoid pregnancy for 12 months and/or normalised B cell function after receiving Rituximab. Oestrogen containing oral contraceptive pills and the morning after pills should be avoided in female TTP patients)~* Patients with an acute deterioration in neurological function which may include encephalopathy, such as altered personality, problems with short term memory and coma can be included when consent has been given by next of kin or from the appropriate legal representative.~Exclusion Criteria:~* All female subjects who are knowingly pregnant or breast feeding or do not use an adequate form of contraception (the effect on the foetus and newborn have not yet been fully established so Rituximab should be avoided in these groups. Male patients receiving Rituximab should ensure adequate contraception for 12 months following treatment).~* Patients who are HIV positive (which does not appear to be antibody mediated, would be unlikely to benefit from Rituximab)~* Patients with childhood TTP~* Patients who have Haemolytic Uraemic Syndrome (HUS) (which is not associated with reduced ADAMTS 13 levels)~* Patients who are post bone marrow transplant - either autologous or allogeneic~* Patients wiht a medical or long term psychiatric condition which, in the opinion of the investigator, contraindicates the patients' participation into the trial~* Previous or concurrent malignancies at other sites, with exception of appropriately treated localized epithelial or cervical cancer. Patients with a history of cured tumours may be entered (\> 5 years).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- no comparator (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: The subject must have:~1. Diagnosis of early to moderate degenerative disc disease (DDD), Modified Pfirrmann Grade 3-7.~2. Chronic low-back pain for at least 6 months prior to screening; unresponsive to at least 3 months of conservative care.~3. Low-back pain of 40 to 90 mm on the VAS and ODI score of 30 to 90.~Exclusion Criteria: The subject is excluded if he/she has:~1. Symptomatic involvement of more than one lumbar disc.~2. Other persistent pain/nerve issues including, for example, radiculopathy, leg pain, cauda equine syndrome, etc.~3. Fracture of the spine, previous lumbar spine surgery or previous treatment of the target disc.~4. Evidence of dynamic instability on lumbar flexion-extension radiographs.~5. Grade 2 or higher spondylolisthesis at the target disc, lumbar spondylitis or other undifferentiated spondyloarthropathy, or Type III Modic changes around the target disc.~6. Clinical suspicion of a full thickness annular tear at the target disc or other abnormal disc morphology.~7. Clinical suspicion of facet pain as primary pain generator.~8. Subjects who test positive for communicable disease, have significant systemic disease, or are prone to infection.~9. Patients who are deemed unsuitable for clinical study participation by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- High Dose IDCT (Type: EXPERIMENTAL): Single intradiscal injection with High Dose IDCT (9M cells).
- Low Dose IDCT (Type: EXPERIMENTAL): Single intradiscal injection with Low Dose IDCT (3M cells).
- Saline (Type: PLACEBO_COMPARATOR): Single intradiscal injection with saline solution.
- Sodium Hyaluronate Vehicle (Type: PLACEBO_COMPARATOR): Single intradiscal injection with Sodium Hyaluronate Vehicle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraarticular Injections of the Hip and Knee With Triamcinolone Versus Ketorolac: A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic, radiographically proven degenerative joint disease in the hip or knee~Exclusion Criteria:~* recent injection in the hip or knee within the previous 3 months~* history of traumatic osteoarthritis or ligamentous reconstruction~* chronic narcotic use~* history of inflammatory or neuropathic arthropathy~* pregnant and/or nursing women~* allergy or strong reaction to study medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ketorolac Intraarticular Hip Injection (Type: EXPERIMENTAL): Patients will receive an intraarticular hip injection with ketorolac.
- Triamcinolone Intraarticular Hip Injection (Type: ACTIVE_COMPARATOR): Patients will receive an intraarticular hip injection with triamcinolone.
- Ketorolac Intraarticular Knee Injection (Type: EXPERIMENTAL): Patients will receive an intraarticular knee injection with ketorolac.
- Triamcinolone Intraarticular Knee Injection (Type: ACTIVE_COMPARATOR): Patients will receive an intraarticular knee injection with triamcinolone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate to severe ARDS, as defined by the Berlin definition, requiring an endotracheal or tracheal tube~* Able to receive investigational medicinal product within 96 hours of meeting the last of the ARDS diagnosis criterion~Exclusion Criteria:~* Concurrent illness that shortens life expectancy to less than 6 months~* Other serious medical or psychiatric illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Low dose MultiStem
- Cohort 2 (Type: EXPERIMENTAL): High dose MultiStem
- Cohort 3 (Type: EXPERIMENTAL): Highest safe MultiStem dose (from Cohorts 1 and 2) or Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* infants 6 to 8 months old inclusive, who were born after full term pregnancy and previously received three doses of both Prevenar and Infanrix-hexa vaccines at least 30 days before study entry~Exclusion Criteria:~* who previously received any meningococcal vaccine;~* who have had a previous confirmed or suspected disease caused by N. meningitidis, C. diphtheriae, C. tetani, Poliovirus, Hepatitis B, Hib, Pneumococcus or B. pertussis;~* who have had household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis (serogroups A, C, W135, or Y), B. pertussis, Hib, C. diphtheriae, Polio, or pneumococcal infection at any time since birth;~* Subjects with any serious, acute or chronic progressive disease

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 8 Months
- Healthy Volunteers: t

Study Arms:
- MenACWY-CRM197 (2 doses) + Concomitant Vaccines (Type: EXPERIMENTAL): Infants received two doses of MenACWY-CRM197 at 6 to 8 and 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months.
- MenACWY-CRM197 (1 dose) + Concomitant Vaccines (Type: EXPERIMENTAL): Infants received one dose of MenACWY-CRM197 at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
- MenC (1 dose) + Concomitant Vaccines (Type: ACTIVE_COMPARATOR): Infants received one dose of MenC vaccine at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Renin Angiotensin System Study (RASS/B-RASS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* type 1 diabetic (DM) for 2-20 yrs~* type 1 DM onset prior to 45; if onset was between ages 31-41, BMI \<26; onset 41-45, positive GAD or ICA required~* normal or increased GFR~* normal BP~* normoalbuminuric (\<20 ug/min on 2 of 3 time overnight urine collections)~Exclusion Criteria:~* type 1 DM duration longer than 20 yrs~* hypertension (\>85/135 mmHg)~* reduced GFR (\<90 ml/min/1.73m2)~* microalbuminuria~* solitary kidney or evidence of unilateral renal disease~* evidence of other important kidney disease by history, ultrasound or biopsy~* other chronic diseases or conditions such as cystic fibrosis, serious mental illness, severe mental retardation, etc.~* pregnancy or females planning pregnancy within 2 years were excluded due to the drugs being used~* compliance (pt not taking at least 85% of two week placebo were excluded)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 61 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female from \>= 1 month to \< 16 years of age. For subjects who are \< 1 year from birth and who were preterm infants, the corrected gestational age should be used for this entry requirement~* Weight \>= 3 kg (6.6 lbs)~* Diagnosis of epilepsy~* Acceptable candidate for venipuncture and intravenous (iv) infusion~* Treatment with \>=1 anti epileptic drug (AED; including BRV) without a change of dose regimen for at least 7 days prior to Screening~* No treatment with vagus nerve stimulation (VNS), OR the subject is being treated with VNS and the settings have been constant for \>=7 days prior to Screening~* For female subjects: not of childbearing potential, OR of childbearing potential and not sexually active/negative pregnancy test, OR of childbearing potential and sexually active/negative pregnancy test/uses medically acceptable contraceptive methods~Exclusion Criteria:~* Subject has previously received iv Brivaracetam (BRV) in this study~* Subject is being treated with BRV at a dose \>5mg/kg/day (rounded) or \>200mg/day for subjects with body weights \>40kg~* Subject requires or is likely to require a change in concomitant antiepileptic drug(s) (AED\[s\]), dose of concomitant AED(s), or formulation of AED(s) during the 7 days prior to the intravenous (iv) pharmacokinetic (PK) Period~* Subject is likely, in the opinion of the Investigator, to require rescue medication during the Initiating Oral BRV (IOB) Treatment or iv PK Periods~* Subject has experienced generalized convulsive status epilepticus in the 28 days prior to Screening or during the Screening Period

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Brivaracetam (Type: EXPERIMENTAL): Brivaracetam will be administered to various age-based cohorts. Cohort 1: Subjects \>=12 to \<16 years; Cohort 2: Subjects \>=6 to \<12 years; Cohort 3: Subjects \>=2 to \<6 years; Cohort 4: Subjects 1 month to \<2 years. Enrollment will be sequential by descending age beginning with Cohort 1. For each cohort, the first half will receive a 15-minute iv infusion. The Data Monitoring Committee (DMC) will then review safety and, as available, PK data to make the following recommendations: the progression of the current cohort (up to 2-minute iv bolus infusion) and progression to initiate enrollment in the preceding cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete